

Resource Summary Report

Generated by [NIF](#) on Aug 31, 2026

BxPC-3

RRID:CVCL_0186

Type: Cell Line

Proper Citation

RRID:CVCL_0186

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0186

Proper Citation: RRID:CVCL_0186

Description: Cell line BxPC-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Pancreatic ductal adenocarcinoma

Defining Citation: [PMID:1630814](#), [PMID:1764370](#), [PMID:3754176](#), [PMID:7961102](#), [PMID:8026879](#), [PMID:8194712](#), [PMID:8286197](#), [PMID:8426738](#), [PMID:9788440](#), [PMID:10027410](#), [PMID:10408907](#), [PMID:11115575](#), [PMID:11169959](#), [PMID:12692724](#), [PMID:15126341](#), [PMID:15367885](#), [PMID:15688027](#), [PMID:16912165](#), [PMID:18298655](#), [PMID:18380791](#), [PMID:20037478](#), [PMID:20164919](#), [PMID:20418756](#), [PMID:21607521](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27073551](#), [PMID:27229158](#), [PMID:27259358](#), [PMID:27397505](#), [PMID:27910856](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:32782605](#), [PMID:35839778](#)

Comments: Caution: Additional TP53 mutation in c.793C>T indicated incorrectly in PubMed=1630814., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: BxPC-3

Synonyms: BxPc-3, BXPC-3, Bx-PC3, BXPC3, BxPC3, BxPc3, Biopsy xenograft of Pancreatic Carcinoma line-3

Cross References: BTO:BTO_0001861, CLO:CLO_0002065, EFO:EFO_0002709, MCCL:MCC:0000077, CLDB:cl516, CLDB:cl517, CLDB:cl518, AddexBio:C0018003/27, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1687, BCRC:60283, BCRJ:0056, BioGRID_ORCS_Cell_line:162, BioSample:SAMN03470942, BioSample:SAMN10987955, cancercellines:CVCL_0186, CCRID:1101HUM-PUMC000274, CCRID:3101HUMTCHu012, Cell_Model_Passport:SIDM00132, CGH-DB:161-1, CGH-DB:9272-4, ChEMBL-Cells:ChEMBL3307637, ChEMBL-Targets:ChEMBL614530, CLS:305031, Cosmic:707248, Cosmic:730531, Cosmic:736269, Cosmic:755301, Cosmic:808164, Cosmic:872995, Cosmic:906693, Cosmic:913310, Cosmic:918055, Cosmic:922251, Cosmic:923165, Cosmic:932515, Cosmic:933516, Cosmic:947403, Cosmic:948372, Cosmic:949321, Cosmic:968108, Cosmic:1006369, Cosmic:1198209, Cosmic:1299295, Cosmic:1366281, Cosmic:1477430, Cosmic:1518232, Cosmic:1534316, Cosmic:1571773, Cosmic:1644317, Cosmic:1768263, Cosmic:1945873, Cosmic:2434095, Cosmic:2820476, Cosmic-CLP:906693, DepMap:ACH-000535, DSMZ:ACC-760, DSMZCellDive:ACC-760, ECACC:93120816, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:906693, GEO:GSM206447, GEO:GSM621894, GEO:GSM784699, GEO:GSM886896, GEO:GSM887961, GEO:GSM1024397, GEO:GSM1374415, GEO:GSM1374416, GEO:GSM1374417, GEO:GSM1588608, GEO:GSM1588620, GEO:GSM1669634, GEO:GSM1906991, GEO:GSM1906992, GEO:GSM1906993, IARC_TP53:312, ICLC:HTL96011, IZSLER:BS TCL 4, KCB:KCB 200428YJ, LiGeA:CCL_491, LINC_S_LDP:LCL-1731, Lonza:1013, PharmacDB:BxPC3_149_2019, PRIDE:PXD003198, PRIDE:PXD030304, PRIDE:PXD032263, Progenetix:CVCL_0186, PubChem_Cell_line:CVCL_0186, SKY/M-FISH/CGH:1995, TOKU-E:707, Ubigen:YC-C015, Wikidata:Q54798758

ID: CVCL_0186

Record Creation Time: 20220427T215417+0000

Record Last Update: 20260829T231656+0000

Ratings and Alerts

No rating or validation information has been found for BxPC-3.

No alerts have been found for BxPC-3.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 1338 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Carta L, et al. (2026) Identification of Small-Molecule Inhibitors that Block the GTP-Binding Pocket of K-Ras and Other Members of the Ras Superfamily of Small GTPases. *Molecular cancer therapeutics*, 25(1), 84.

Shi X, et al. (2026) Tumor-Derived LAMB3 Drives Immunosuppressive LRRC15+ Fibroblast Formation During Pancreatic Ductal Adenocarcinoma Development. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e20029.

De Boni L, et al. (2026) Placing purines in precision medicine: Targeting a metabolic reliance in KRAS-mutant tumors. *iScience*, 29(3), 114954.

Zhang R, et al. (2026) Targeting a Glutamic Acid in PDE γ with Fluoromethyl-Aryl Electrophiles Impairs K-Ras Signaling. *Journal of medicinal chemistry*.

Zhang W, et al. (2026) Membrane Curvature Activates Src kinase and Promotes Metastatic Cancer Cell Survival. *bioRxiv : the preprint server for biology*.

Yuan YC, et al. (2026) Deep Learning-Powered Scalable Cancer Organ Chip for Cancer Precision Medicine. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(26), e16660.

Liu X, et al. (2026) Connexin 26 Functions as a Direct Transcriptional Regulator During the Cochlea Development. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e14136.

Li Z, et al. (2026) An Insulin-Exosome-TNFAIP8 Axis Drives Stromal Fibrosis and Therapeutic Resistance in Pancreatic Cancer. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(24), e15606.

Kan T, et al. (2026) Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab-paclitaxel. *International journal of cancer*, 158(12), 3091.

Bandi DSR, et al. (2026) ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma. *bioRxiv : the preprint server for biology*.

Smith JP, et al. (2026) Interruption of cross-communication pathways alters the immune cell signature of pancreatic cancer and decreases tumor growth. *Cell communication and signaling : CCS*, 24(1), 71.

Yang J, et al. (2026) A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(12), 2479.

Pan CH, et al. (2026) Mitochondrial-Localized Keratin 17 Promotes Chemoresistance in Basal-like Pancreatic Cancer. *Cancer research*, 86(12), 2935.

Wang F, et al. (2026) Lactate Facilitates the Survival and Invasion of Pancreatic Cancer Cells Under Glucose Deprivation. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 40(7), e71726.

Gowada D, et al. (2026) Pyrazolo-quinolinone suppresses epithelial-mesenchymal transition by targeting the CXCR4/NF- κ B axis in human pancreatic cancer cells. *Pathology, research and practice*, 286, 156547.

Yokoyama H, et al. (2026) Glypican-1-targeted antibody-drug conjugate shows therapeutic efficacy in lung squamous cell carcinoma. *Lung cancer (Amsterdam, Netherlands)*, 217, 109431.

Saini P, et al. (2026) Targeting Interactions Between Siglec-10 and α 5 β 1 Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer. *Cancer research*, 86(1), 99.

Armstrong A, et al. (2026) Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(3), 611.

Wang J, et al. (2026) Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers. *Cell reports. Medicine*, 7(2), 102577.

Anh DXT, et al. (2026) GlycoChat Uncovers Glycan-Lectin Circuits in the Tumor Microenvironment of Pancreatic Cancer. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(14), e14735.